"Waldenström's Macroglobulinemia: Subtype Review." Lymphoma Coalition, August 2016. This is an overview of the disease prepared by the Lymphoma Coalition with review and editing assistance provided by the IWMF. It covers the basic biology of WM, along with current treatment recommendations from NCCN and from Dr. Steven Treon of the Bing Center for WM. Special sections of this report look at treatment availability and clinical trial activity in multiple countries and discuss the patient experience in terms of physical symptoms and psychological and social factors that impact the patient's sense of well being.
"Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia." Jorge J. Castillo et al, British Journal of Haematology, 2016. A multi-institutional task force was formed during the 8th International Workshop for WM in London to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, recommendations are provided for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis, and imaging studies. Guidance is also provided on the initial evaluation of special situations, such as anemia, hyperviscosity, neuropathy, Bing-Neel syndrome, and amyloidosis. (Article provided with permission of Jorge J. Castillo of the Bing Center for Waldenstrom's Macroglobulinemia.)
"How I Treat Waldenstrom Macroglobulinemia" Treon, S. P., Blood. First Edition Paper, prepublished online May 22, 2015, DOI 10.1182. Treatment recommendations published by Dr. Steven Treon of the Dana-Farber Cancer Institute in 2015. (Article provided with permission of the Bing Center for Waldenstrom's Macroglobulinemia.)
"NCCN Clinical Practice Guidelines in Oncology for Macroglobulinemia/Lymphoplasmacytic Lymphoma." The NCCN is a non-profit alliance of 23 cancer centers in the U.S. whose goal is to improve the quality and effectiveness of care provided to cancer patients. They provide updated guidelines based on the most current and up-to-date diagnosis and treatment guidelines available. You must establish an account on the NCCN website to login and view these guidelines.
A review of recent advances in the biology of WM and the current therapeutic options for untreated and relapsed WM patients, including a discussion of prognostic factors. Jorge J. Castillo, Irene M. Ghobrial, and Steven P. Treon from Dana-Farber Cancer Institute. "Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia." Cancer Treatment and Research, 2015. (Provided with permission from Dr. Castillo).
"Waldenström macroglobulinemia: From Biology to Treatment." Ilyas Sahin, Houry Leblebjian, Steven P. Treon, and Irene M. Ghobrial, Dana-Farber Cancer Institute. A 2013-2014 review of what is known about WM, its biology and treatment, and a summary of novel agents that are becoming available. The article was published in Expert Review of Hematology, and is provided with the permission of the authors.
"The genomic landscape of Waldenstrom's Macroglobulinemia is characterized by highly rercurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis." Steven P. Treon et al, Dana-Farber Cancer Institute, Boston, MA. A technical discussion of the recently-discovered mutations prevalent in WM patients that appeared in Blood in December 2013 and is provided with the permission of the authors. The research leading to this discovery was funded in part with the support of the IWMF.
"Novel treatment options for Waldenstrom Macroglobulinemia." Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, MA. Dr. Ghobrial provides her PowerPoint presentation at the Lymphoma Research Foundation Educational Forum in New York City on September 24-26, 2013..
"Waldenström macroglobulinemia." Stephen M. Ansell, Mayo Clinic, Rochester, MN. Dr. Ansell provides his PowerPoint presentation at the Lymphoma Research Foundation Ed Forum in New York City on September 24-26, 2013.
"Haematopoietic Stem Cell Mobilisation and Apheresis: A Practical Guide for Nurses and Other Allied Health Care Professionals." Developed in 2013 by the European Group for Bone and Marrow Transplantation, this guide discusses stem cell collection, storage, and transplantation procedures, which may vary somewhat from country to country.
"Are you sure this is Waldenstrom macroglobulinemia?" Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, MA. Dr. Ghobrial presents a comprehensive summary of the symptoms and manifestations of WM in an article from the 2012 ASH Education Book.
"MYD88 L265P Somatic Mutation in Waldenström’s Macroglobulinemia." Steven P. Treon et al, Dana-Farber Cancer Institute, Boston MA. This article, published in the New England Journal of Medicine in 2012, outlines the seminal discovery of the prevalence of the MYD88 L265 P mutation in WM patients. The research leading to this discovery was funded in part with the support of the IWMF.
"Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines." Stephen M. Ansell et al, Mayo Clinic. Mayo Clinic researchers provide their recommendations on timing and choice of therapy. These guidelines undergo periodic review and updating.
"Novel treatment regimens for Waldenström's macroglobulinemia." Ramón Garcia-Sanz and Enrique M. Ocio. A downloadable (but not printable) 2010 review in Expert Review of Hematology on the use of new combinations and new drugs in patients with WM at different stages of the disease. The article is provided with permission from the journal.
"Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients." Megan Rourke, Kenneth C. Anderson, and Irene M. Ghobrial, Dana-Farber Cancer Institute. This 2010 article in Leukemia & Lymphoma reviews 44 published clinical trials in WM.
A variety of articles on the biology and potential side effects of rituximab (Rituxan) that were published in the journal Seminars in Hematology, Volume 47, Issue 2, April 2010. (Articles provided with permission of Elsevier/Rightslink Copyright Clearance Center.)